DE69734574D1 - Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse - Google Patents

Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse

Info

Publication number
DE69734574D1
DE69734574D1 DE69734574T DE69734574T DE69734574D1 DE 69734574 D1 DE69734574 D1 DE 69734574D1 DE 69734574 T DE69734574 T DE 69734574T DE 69734574 T DE69734574 T DE 69734574T DE 69734574 D1 DE69734574 D1 DE 69734574D1
Authority
DE
Germany
Prior art keywords
gene therapy
adenovirenvektoren
recombinant
human cancer
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69734574T
Other languages
English (en)
Other versions
DE69734574T2 (de
Inventor
Falleur Boon
Marie-Therese Duffour
Hedi Haddada
Christophe Lurquin
Michel Perricaudet
Catherine Uyttenhoveghesquiere
Guy Warnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTELION, VITRY SUR SEINE, FR
Ludwig Institute for Cancer Research London
Original Assignee
Aventis Pharma SA
Ludwig Institute for Cancer Research London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA, Ludwig Institute for Cancer Research London filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of DE69734574D1 publication Critical patent/DE69734574D1/de
Publication of DE69734574T2 publication Critical patent/DE69734574T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
DE69734574T 1996-03-14 1997-03-12 Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse Expired - Fee Related DE69734574T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9603207A FR2746110B1 (fr) 1996-03-14 1996-03-14 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
FR9603207 1996-03-14
PCT/FR1997/000435 WO1997034009A1 (fr) 1996-03-14 1997-03-12 Vecteurs adenoviraux recombinants pour la therapie genique des tumeurs humaines

Publications (2)

Publication Number Publication Date
DE69734574D1 true DE69734574D1 (de) 2005-12-15
DE69734574T2 DE69734574T2 (de) 2006-07-13

Family

ID=9490181

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69734574T Expired - Fee Related DE69734574T2 (de) 1996-03-14 1997-03-12 Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse

Country Status (19)

Country Link
US (1) US20030082150A1 (de)
EP (1) EP0889969B1 (de)
JP (1) JP2000507229A (de)
KR (1) KR19990087718A (de)
CN (1) CN1218512A (de)
AT (1) ATE309382T1 (de)
AU (1) AU732288B2 (de)
BR (1) BR9707994A (de)
CA (1) CA2248612A1 (de)
CZ (1) CZ295967B6 (de)
DE (1) DE69734574T2 (de)
DK (1) DK0889969T3 (de)
ES (1) ES2252779T3 (de)
FR (1) FR2746110B1 (de)
HU (1) HUP9902150A3 (de)
IL (1) IL126152A0 (de)
NO (1) NO984052L (de)
SK (1) SK124698A3 (de)
WO (1) WO1997034009A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015638A2 (en) * 1996-10-07 1998-04-16 Ludwig Institute For Cancer Research Replication-defective adenoviruses for cancer immunotherapy
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
ATE346925T1 (de) * 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
AU2002258631B2 (en) * 2001-03-27 2007-05-17 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
DE60315628T2 (de) 2002-04-09 2008-06-05 Sanofi Pasteur Ltd., Toronto Modifizierte cea nucleinsäure und expressionsvektoren
JP2005523942A (ja) * 2002-04-30 2005-08-11 アヴィオル セラピューティクス インコーポレイテッド 免疫療法のためのアデノウイルスベクター
CN1327000C (zh) * 2002-09-06 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 靶向黑色素瘤的可复制性腺病毒穿梭载体及腺病毒
US20040223949A1 (en) * 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
ATE506444T1 (de) * 2003-10-08 2011-05-15 Sanofi Pasteur Ltd Modifizierter cea/b7-vektor
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
KR100356615B1 (ko) * 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용

Also Published As

Publication number Publication date
EP0889969B1 (de) 2005-11-09
JP2000507229A (ja) 2000-06-13
CZ295967B6 (cs) 2005-12-14
DE69734574T2 (de) 2006-07-13
EP0889969A1 (de) 1999-01-13
NO984052D0 (no) 1998-09-03
CZ291598A3 (cs) 1998-12-16
IL126152A0 (en) 1999-05-09
SK124698A3 (en) 1999-05-07
CA2248612A1 (fr) 1997-09-18
ATE309382T1 (de) 2005-11-15
HUP9902150A2 (hu) 1999-11-29
CN1218512A (zh) 1999-06-02
ES2252779T3 (es) 2006-05-16
NO984052L (no) 1998-09-03
AU732288B2 (en) 2001-04-12
HUP9902150A3 (en) 2000-12-28
FR2746110A1 (fr) 1997-09-19
US20030082150A1 (en) 2003-05-01
DK0889969T3 (da) 2006-03-27
WO1997034009A1 (fr) 1997-09-18
AU2164197A (en) 1997-10-01
KR19990087718A (ko) 1999-12-27
BR9707994A (pt) 1999-07-27
FR2746110B1 (fr) 1998-04-17

Similar Documents

Publication Publication Date Title
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
DE69734574D1 (de) Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
HUP0203035A2 (hu) Prosztatarák terápiájára és diagnózisára alkalmas vegyületek és eljárások
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
NO883896L (no) Fremgangsmaate til fremstilling av konjugater av cytokinermed menneskelig immunglobulin.
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
IL145731A0 (en) A polypetide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
ATE79763T1 (de) Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
PL1699480T3 (pl) Allogeniczny przeciwnowotworowy czynnik terapeutyczny
DE60036105D1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
ATE514780T1 (de) Zusammensetzungen für die therapie und diagnose von brustkrebs und verwendung davon
AR019844A1 (es) Polipeptidos composicion farmaceutica, procedimiento para preparar dicha composicion metodo para tratar y prevenir el cancer y metodo para inhibir elcrecimiento de celulas tumorales
PT1007717E (pt) Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta
ES8600518A1 (es) Metodo in vitro para detectar un estado maligno en un paciente humano.
ATE193451T1 (de) Verotoxin pharmazeutische zusammensetzungen und damit medizinische behandlungen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CENTELION, VITRY SUR SEINE, FR

Owner name: LUDWIG INSTITUTE FOR CANCER RESEARCH, LONDON, GB

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee